JAZZ 241220 220.00P (JAZZ241220P220000) Stock Options, News & Quotes

US OptionsDetailed Quotes

JAZZ241220P220000

Watchlist

100.50
0.000.00%

15min DelayClose Nov 15 15:59 ET

0.00High0.00Low

Intraday

5D
Daily

News

Jazz Pharmaceuticals' (NASDAQ:JAZZ) Performance Is Even Better Than Its Earnings Suggest
Yahoo FinanceNov 14 06:17 ET
Jazz Pharmaceuticals Insider Sold Shares Worth $456,617, According to a Recent SEC Filing
MT NewswiresNov 13 17:46 ET
Baupost's Top Q3 Trades Include Jazz Exit, New Dollar General Stake
Seeking AlphaNov 13 17:36 ET
Jazz (JAZZ) Upgraded to Buy: Here's Why
Zacks Nov 13 11:15 ET
Wall Street Analysts See a 37.65% Upside in Jazz (JAZZ): Can the Stock Really Move This High?
Zacks Nov 13 09:05 ET
Jazz Pharmaceuticals Third Quarter 2024 Earnings: Beats Expectations
Yahoo FinanceNov 11 13:18 ET

Comments

10xStockPicks

Oct 24 07:55

Hugely Undervalued $2 Biotech With 21% Held Short $16 Price Target, Takeover Candidate, Soon Profitable

Esperion $Esperion Therapeutics (ESPR.US)$ We reiterate Strong Buy rating. Esperion has the only FDA approved statin alternative drugs NEXLIZET & NEXLETOL for Primary Prevention, an estimated 21 Million Americans are Statin intolerant and or maxed out on Statin drugs and need additional lowering. Over 71 million Americans take statin drugs, we see continued prescription growth & expect over 5...

+20

Stock_Drift

Sep 16 06:45

$Jazz Pharmaceuticals (JAZZ.US)$

Meltyy

May 22 02:52

Biotech Stock Catalyst Watchlist 👀

🎯 Ph 2 readouts in Q2 2024...
$Iovance Biotherapeutics (IOVA.US)$ Phase 2
$Supernus Pharmaceuticals (SUPN.US)$ Phase 2a
$BRANDES INTERNATIONAL ETF (BINV.US)$ Phase 2a
$MorphoSys (MOR.US)$ Phase 2
$Nuvation Bio (NUVB.US)$ Phase 2
$ALX Oncology (ALXO.US)$ Phase 2
$BioXcel Therapeutics (BTAI.US)$ Phase 2
$Purple Biotech (PPBT.US)$ Phase 2
$Arcus Biosciences (RCUS.US)$ Phase 2
$Medicenna Therapeutics (MDNAF.US)$ Phase 2b
$Affimed NV (AFMD.US)$ Phase 2
$Barinthus Biotherapeutics (BRNS.US)$ Phase 2b...

Moomoo AI

Mar 27 06:55

Despite Jazz Pharmaceuticals' revenue growth and profitability, its share price drop may signal unresolved issues. The long-term share price weakness could be a bad sign, yet contrarian investors might see a potential turnaround opportunity.

5.0% Earnings Growth Over 3 Years Has Not Materialized Into Gains for Jazz Pharmaceuticals (NASDAQ:JAZZ) Shareholders Over That Period

Moomoo AI

Feb 29 08:59

The low ROE and high debt usage of Jazz Pharmaceuticals make it a less exciting investment at the moment. The company's performance could be impacted if it was unable to borrow as easily in changing credit markets.

Can Jazz Pharmaceuticals Plc (NASDAQ:JAZZ) Improve Its Returns?